On September 19, 2023, Liminal BioSciences received the final approval from the Ontario Superior Court of Justice for its plan of arrangement under section 192 of the Canada Business Corporations Act. This significant development involves Structured Alpha LP (SALP) acquiring all the outstanding common shares of Liminal BioSciences, which are not currently owned by SALP or its affiliates and associates. The purchase price for these shares is set at US$8.50 per Share, payable in cash.
The completion of this transaction is anticipated to take place on or around September 26th, 2023, subject to the fulfillment or waiver of various customary closing conditions typically associated with such transactions. This marks a crucial step forward for Liminal BioSciences and demonstrates their commitment to strategic growth and development in the industry.
Liminal BioSciences Inc.
Updated on: 19/09/2023
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
We did not find social sentiment data for this stock
There are no analysts data to display
LMNL Stock Analysis: Limited Financial Data and Lack of Competitor Information May Cause Investor Uncertainty
LMNL stock experienced a relatively uneventful day on September 19, 2023, with no change in price throughout the trading day. The stock opened and closed at $8.47, with a limited range of $8.47. LMNL is a biotechnology company with a market capitalization of $27.5 million. The stock’s volume on September 19 was 5,200 shares, suggesting lower-than-average trading activity. LMNL’s earnings growth for the last and current year is unknown, and there are no projections for the next five years. The company’s revenue growth for the previous year was -39.94%, indicating a significant decline. The price-to-earnings ratio is listed as NM, and the price-to-sales ratio is 32.75. The price-to-book ratio is 0.98. No competitor data is available for LMNL, making it difficult to assess its relative performance within the industry. The next reporting date and earnings per share forecast are unknown. The limited financial data and transparency, along with the absence of competitor data, may contribute to investor uncertainty and potential volatility in the stock.
LMNL Stock Performance Shows Promising Signs for Liminal BioSciences Inc. on September 19, 2023
LMNL stock performances on September 19, 2023, have shown promising signs for Liminal BioSciences Inc. According to data sourced from CNN Money, the one analyst offering a 12-month price forecast for the company has a median target of 19.39, with both the high and low estimates also at 19.39. This median estimate indicates a significant increase of 128.93% from the last recorded price of 8.47.
The current consensus among one polled investment analyst is to hold stock in Liminal BioSciences Inc. This rating has remained steady since July.
While there is no specific information available regarding the current quarter’s earnings per share or sales for Liminal BioSciences Inc., it is important to note that the reporting date is yet to be determined (TBD).
The median target price forecast of 19.39 suggests that analysts are optimistic about the future prospects of Liminal BioSciences Inc. This positive sentiment may be attributed to various factors, such as potential product developments, industry trends, or market conditions.
Investors should consider the analyst’s median target price as a guideline for potential future gains. However, it is essential to conduct thorough research and analysis before making any investment decisions. Factors such as the company’s financial health, competitive landscape, and overall market conditions should be taken into account.
As with any investment, there are inherent risks involved, and it is advisable to consult with a financial advisor or professional before making any investment decisions. By staying informed and conducting due diligence, investors can make more informed choices regarding their investment portfolios.